The retrospective CNODES study also showed that GLP-1 agonists did not increase heart failure hospitalization among patients with (0.5 vs 0.7%, HR 0.75, 95% CI, 0.22–2.51) or without a history of heart failure (1.0 vs 0.9%, HR 0.95, 95% CI 0.83–1.10) [69]. This evidence concerns the gene GLP1R and heart failure.